Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects
- PMID: 15193831
- DOI: 10.1016/j.ijcard.2003.08.003
Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects
Abstract
Background: Hydroxymethyl-glutaryl-CoA-reductase inhibitors (statins) reduce cardiovascular events by cholesterol lowering as well as non-lipid related actions. Among them, the modulation of fibrinolysis could play a relevant role in vascular protection. Atorvastatin is able of reducing platelet activity and thrombin generation before low-density lipoprotein cholesterol (LDL-C) decrease in hypercholesterolemic subjects in which coagulation and fibrinolysis are linked by the activation of thrombin activable fibrinolysis inhibitor (TAFI). The aim of our study was to evaluate whether atorvastatin could modulate fibrinolysis by interactions with endothelial mechanisms and thrombin generation.
Methods: Forty-four pure hypercholesterolemic subjects (26 M, 18 F, mean age 52.7+/-13.7, LDL-C 194.8+/-9.3t mg/dl) were evaluated for plasmin-antiplasmin complexes (PAP), tissue-plasminogen acivator (t-PA) and its inhibitor (PAI-1) (ELISA), TAFI activity (HPLC), platelet P-selectin (P-sel) (cytofluorymetric detection), platelet-dependent thrombin generation (PDTG, coagulative-chromogenic method) and lipid profile at baseline and after 7, 14, 28 and 90 days of atorvastatin (10 mg/die) treatment.
Results: PAP were significantly reduced at baseline in hypercholesterolemic versus control subjects (P<0.05) and were related to P-sel (P<0.01), PDTG (P<0.01) and its inhibitor (PAI-1) after venous occlusion (VO) (P<0.05). Atorvastatin induced a significant increase of PAP at T(2) related to modifications of P-sel (P<0.01) and PDTG (P<0.01) before significant LDL-C reduction (P=0.132). PAI-1 was significantly changed at T(3) with relation to LDL-C (P<0.01), Von Willebrand factor (VWF) (P<0.01) and sE-sel (P<0.05).
Conclusions: The profibrinolytic activity of atorvastatin in hypercholesterolemic subjects is related, initially, to the positive effects exerted on platelet function and thrombin generation which can modulate fibrinolysis by TAFI activity.
Similar articles
-
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.Nutr Metab Cardiovasc Dis. 2001 Dec;11(6):378-87. Nutr Metab Cardiovasc Dis. 2001. PMID: 12055702 Clinical Trial.
-
Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.Int J Clin Pharmacol Res. 2001;21(3-4):147-55. Int J Clin Pharmacol Res. 2001. PMID: 12067144
-
Dyslipidemias and fibrinolysis.Ital Heart J. 2002 Oct;3(10):579-86. Ital Heart J. 2002. PMID: 12478815
-
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.Drugs. 2003;63(17):1821-54. doi: 10.2165/00003495-200363170-00005. Drugs. 2003. PMID: 12921488 Review.
-
[Do anti-lipemic agents only work by their lipid-lowering effect?].Ann Cardiol Angeiol (Paris). 1999 Nov;48(9-10):656-60. Ann Cardiol Angeiol (Paris). 1999. PMID: 12555474 Review. French. No abstract available.
Cited by
-
Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study.Clin Drug Investig. 2010;30(7):453-60. doi: 10.2165/11536270-000000000-00000. Clin Drug Investig. 2010. PMID: 20441243
-
Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins.Medicine (Baltimore). 2018 Apr;97(17):e0589. doi: 10.1097/MD.0000000000010589. Medicine (Baltimore). 2018. PMID: 29703054 Free PMC article.
-
Lipid-lowering efficacy of atorvastatin.Cochrane Database Syst Rev. 2015 Mar 12;2015(3):CD008226. doi: 10.1002/14651858.CD008226.pub3. Cochrane Database Syst Rev. 2015. PMID: 25760954 Free PMC article.
-
Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia.J Natl Med Assoc. 2006 Apr;98(4):627-30. J Natl Med Assoc. 2006. PMID: 16623076 Free PMC article. Clinical Trial.
-
Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity.Ann Surg. 2007 Feb;245(2):176-84. doi: 10.1097/01.sla.0000236627.07927.7c. Ann Surg. 2007. PMID: 17245169 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous